FrancophonIA/ELRC3.0 huggingface dataset:
English: The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the Caelyx plus bortezomib combination therapy patients.
Slovenian: Za bolnike, zdravljene samo z bortezomibom, je bilo mediano OS 30,8 mesecev (95% IZ; 25,2-36,5 mesecev) za bolnike, zdravljene z zdravilom Caelyx v kombinaciji z bortezomibom, pa 33,0 mesecev (95% IZ; 28,9-37,1 meseca).
English: For multiple myeloma patients treated with Caelyx in combination with bortezomib who experience PPE or stomatitis, the Caelyx dose should be modified as described in Table 1 and 2 above respectively.
Slovenian: Pri bolnikih z diseminiranim plazmocitomom, ki se zdravijo z zdravilom Caelyx v kombinaciji z bortezomibom in pri katerih se pojavi palmarno-plantarna eritrodisestezija (PPE) oziroma stomatitis, je treba odmerek zdravila Caelyx prilagoditi, kot je opisano v Preglednicah 1 in 2 zgoraj.
English: More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated
Slovenian: Bolj specifičen način ocenjevanja in spremljanja delovanja srca od EKG je merjenje iztisnega deleža levega prekata z ehokardiografijo ali, še bolje, z multiplo proženo angiografijo (Multiple Gated Angiography - MUGA).
English: Pharmacokinetic parameters in Caelyx-treated AIDS-KS patients Mean + standard error
Slovenian: Farmakokinetični parametri zdravila Caelyx pri bolnikih s Kaposijevim sarkomom, povezanim z aidsom Srednja vrednost ± standardna napaka
English: Studies in rabbits have shown that the cardiotoxicity of Caelyx is reduced compared with conventional doxorubicin hydrochloride preparations.
Slovenian: Raziskave pri kuncih so pokazale, da je kardiotoksičnost zdravila Caelyx manjša kot pri standardnih pripravkih doksorubicinijevega klorida.
English: Adverse drug reactions identified during the post-marketing experience with Caelyx are described in Table 9.
Slovenian: Neželeni učinki, ugotovljeni v obdobju trženja zdravila Caelyx, so opisani v Preglednici 9.
English: Very common side effects (may affect more than 1 in 10 people) - redness, swelling and sores on the palms of your hands and feet.
Slovenian: Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) - pordelost ter rane ali otekanje dlani in stopal.
English: The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m 2) is similar to the 20 mg/m 2 profile in patients with AIDS-KS (see section 4.8).
Slovenian: Kardialni varnostni profil zdravila pri režimu odmerjanja, priporočenem za rak dojk in rak jajčnikov (50 mg/m 2), je podoben kot pri odmerjanju 20 mg/m 2 za bolnike, ki imajo z aidsom povezan
English: Caelyx will be given to you by your doctor in a drip (infusion) into a vein.
Slovenian: Zdravnik vam bo zdravilo Caelyx dal v (kapalni) infuziji v veno.
English: Caelyx is used to treat cancer of the breast in patients at risk for heart problems.
Slovenian: Zdravilo Caelyx uporabljamo za zdravljenje raka dojk pri bolnicah, s tveganjem zaradi težav s srcem.
English: In patients with AIDS-KS, infusion-associated reactions, were characterised by flushing, shortness of breath, facial oedema, headache, chills, back pain, tightness in the chest and throat and/or hypotension and can be expected at the rate of 5% to 10%.
Slovenian: Pri bolnikih s Kaposijevim sarkomom, povezanim z aidsom, so bili za infuzijske reakcije značilni rdečica, težko dihanje, edem obraza, glavobol, mrzlica, bolečine v hrbtu, tiščanje v prsih in žrelu in/ali hipotenzija in te lahko pričakujete v 5 do 10% primerov.
English: Type I glass vials, each with a siliconised grey bromobutyl stopper, and an aluminium seal, with a deliverable volume of 10 ml (20 mg) or 25 ml (50 mg).
Slovenian: Viale (steklo tipa I) s silikoniziranim sivim brombutilnim zamaškom in aluminijasto zaporko, ki vsebujejo po 10 ml (20 mg) ali 25 ml (50 mg) uporabnega volumna.
English: Pruritus, papular rash, allergic dermatitis, erythema, skin hyperpigmentation, petechiae, alopecia, medicine eruption
Slovenian: pruritus, papulozni izpuščaj, alergijski dermatitis, eritem, hiperpigmentacija kože, petehije, alopecija, medikamentozni izpuščaj
English: Caelyx 2 mg/ml concentrate for solution for infusion
Slovenian: Caelyx 2 mg/ml koncentrat za raztopino za infundiranje
English: If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
Slovenian: Če to še vedno dobro prenaša, lahko infuzijo dokončate v naslednji uri, da bo skupni čas infundiranja 90 minut
English: How much Caelyx is given
Slovenian: Koliko zdravila Caelyx boste prejeli
English: Sepsis related to leukopaenia was observed infrequently (< 1%).
Slovenian: V redkih primerih so opažali sepso, povezano z levkopenijo (< 1%).
English: The recommended dose of Caelyx for AIDS-KS patients is 20 mg/m2 every two-to-three weeks.
Slovenian: Priporočeni odmerek zdravila Caelyx za bolnike, ki imajo z aidsom povezani Kaposijev sarkom, je 20 mg/m2 na vsaka dva do tri tedne.
English: Treatment of acute overdose of the severely myelosuppressed patient consists of hospitalisation, antibiotics, platelet and granulocyte transfusions and symptomatic treatment of mucositis.
Slovenian: Zdravljenje akutnega predoziranja pri močno mielosuprimiranih bolnikih obsega bolnišnično zdravljenje z antibiotiki, transfuzijami trombocitov in granulocitov ter simptomatskim zdravljenjem mukozitisa.
English: 512 patients with ovarian cancer (a subset of 876 solid tumour patients) were treated with Caelyx at a dose of 50 mg/m2 in clinical trials.
Slovenian: V kliničnih preskušanjih so 512 bolnic z rakom jajčnikov (podskupina 876 bolnic s solidnimi tumorji) zdravili z zdravilom Caelyx v odmerku 50 mg/m2.
English: Sepsis related to leukopaenia was rarely (< 1%) observed.
Slovenian: Z levkopenijo povezano sepso so opazili redko (< 1%).
English: A phase III randomised, parallel-group, open-label, multicentre study comparing the safety and efficacy of Caelyx plus bortezomib combination therapy with bortezomib monotherapy in patients with multiple myeloma who have received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy, was conducted in 646 patients.
Slovenian: Pri 646 bolnikih je bila opravljena randomizirana, odprta, multicentrična študija faze III pri vzporednih skupinah za primerjavo varnosti in učinkovitosti kombinirane terapije z zdravilom Caelyx in bortezomibom in monoterapije z bortezomibom pri bolnikih z diseminiranim plazmocitomom, ki so prejeli najmanj eno predhodno terapijo in pri katerih bolezen ni napredovala med prejemanjem antraciklinske terapije.
English: The treatments were similar in the sub-group of patients with platinum-refractory disease: HR of 1.069 (95% CI: 0.823; 1.387), p=0.618.
Slovenian: Terapija je bila podobna v podskupini bolnic z rakom, ki se ni odzival na platinsko kemoterapijo: razmerje med tveganji (HR) je bilo 1,069 (95% IZ; 0,823, 1,387), p=0,618.
English: Neutropaenia, thrombocytopaenia, and anaemia were the most frequently reported haematologic events reported with both combination therapy of Caelyx plus bortezomib and bortezomib monotherapy.
Slovenian: Nevtropenija, trombocitopenija in anemija so bili najpogosteje poročani hematološki učinki tako pri kombinirani terapiji z zdravilom Caelyx in bortezomibom kot pri monoterapiji z bortezomibom.
English: If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.
Slovenian: Če se pojavi ta sprememba, premislite o potrebi po endomiokardni biopsiji, ki je najbolj dokončna preiskava za ugotovitev okvare miokarda zaradi antraciklinov.
English: 100 out of 929 patients (10.8%) with solid tumours were described as having an infusion-associated reaction during treatment with Caelyx as defined by the following Costart terms: allergic reaction, anaphylactoid reaction, asthma, face oedema, hypotension, vasodilatation, urticaria, back pain, chest pain, chills, fever, hypertension, tachycardia, dyspepsia, nausea, dizziness, dyspnoea, pharyngitis, rash, pruritus, sweating, injection site reaction and medicinal product interaction.
Slovenian: 100 od 929 bolnikov (10,8%) s solidnimi tumorji je imelo med zdravljenjem z zdravilom Caelyx infuzijsko reakcijo, kot jo opredeljujejo naslednji izrazi Costart: alergijska reakcija, anafilaktoidna reakcija, astma, edem obraza, hipotenzija, vazodilatacija, urtikarija, bolečine v hrbtu, bolečine v prsih, mrzlica, zvišana telesna temperatura, hipertenzija, tahikardija, dispepsija, slabost, omotica, dispneja, faringitis, izpuščaj, srbenje, znojenje, reakcija na mestu injekcije in medsebojno delovanje zdravil.
English: Subcutaneous tolerance studies indicate that Caelyx, as against standard doxorubicin hydrochloride, causes slighter local irritation or damage to the tissue after a possible extravasation.
Slovenian: Raziskave subkutane tolerance za zdravilo kažejo, da zdravilo Caelyx v primerjavi s standardnim doksorubicinijevim kloridom po morebitni ekstravazaciji povzroči manj lokalnega draženja oz. poškodbe tkiva.
English: It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects.
Slovenian: Na splošno menijo, da je večina citotoksičnih učinkov posledica zavore sinteze DNA, RNA in beljakovin.
English: Common adverse events which led to treatment discontinuation of bortezomib and Caelyx included PPE, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, thrombocytopaenia, decreased ejection fraction, and fatigue.
Slovenian: Pogosti neželeni učinki, ki so vodili do ukinitve zdravljenja z bortezomibom in zdravilom Caelyx, so bili med drugim: PPE, nevralgija, periferna nevropatija, periferna senzorična nevropatija, trombocitopenija, zmanjšana iztisna frakcija srca in utrujenost.
English: MODIFICATION
Slovenian: PRILAGODITEV
English: PPE was reported in 16% of multiple myeloma patients treated with Caelyx plus bortezomib combination therapy.
Slovenian: O PPE so poročali pri 16% bolnikov z diseminiranim plazmocitomom, zdravljenih z zdravilom Caelyx v kombinaciji z bortezomibom.
English: For more detailed information on bortezomib dosing and dosage adjustments, see the SPC for bortezomib.
Slovenian: Za podrobnejše informacije o odmerjanju bortezomiba in prilagajanju odmerka glejte povzetek glavnih značilnosti zdravila za bortezomib.
English: Caelyx is not recommended in patients below 18 years of age.
Slovenian: Zdravljenje bolnikov, mlajših od 18 let, z zdravilom Caelyx ni priporočljivo.
English: During repeat dose toxicology studies in dogs, an acute response characterised by hypotension, pale mucous membranes, salivation, emesis and periods of hyperactivity followed by hypoactivity and lethargy was observed following administration of pegylated liposomes (placebo).
Slovenian: Med toksikološkimi raziskavami uporabe večkratnih odmerkov zdravila pri psih so po uporabi pegiliranih liposomov (placeba) opažali akutni odziv s hipotenzijo, bledico sluznic, slinjenjem, emezo in obdobjem hiperaktivnosti, ki sta ji sledili hipoaktivnost in letargija.
English: Investigations common weight loss
Slovenian: Preiskave pogosti izguba telesne mase
English: Although no studies have been conducted with Caelyx, doxorubicin hydrochloride, the pharmacologically active ingredient of Caelyx, is mutagenic and carcinogenic.
Slovenian: Čeprav z zdravilom Caelyx niso opravili raziskav mutagenosti in kancerogenosti, je doksorubicinijev klorid, farmakološka učinkovina v zdravilu Caelyx, mutagen in kancerogen.
English: Caelyx, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies.
Slovenian: Kot druga zdravila doksorubicinijevega klorida lahko tudi zdravilo Caelyx okrepi toksičnost drugih zdravil proti raku.
English: Standard doxorubicin hydrochloride displays extensive tissue distribution (volume of distribution: 700 to 1,100 l/m 2) and a rapid elimination clearance (24 to
Slovenian: Standardni doksorubicinijev klorid se izdatno porazdeli po tkivih (volumen porazdelitve: od 700 do 1.100 l/m2) in ima hiter eliminacijski očistek (24 to 73 l/uro/m2).
English: Uncommon side effects (may affect up to 1 in 100 people) - confusion; - inflammation of the veins and formation of blood clots in the veins which could lead to blockage of blood flow to your lungs causing difficulty breathing, chest pain and palpitations; - abnormal heart rhythm, heart beat feels fast or uneven (palpitations), heart failure, which makes you short of breath and may lead to swollen legs, cardiac arrest.
Slovenian: Občasni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov) - zmedenost - vnetje ven in nastanek krvnih strdkov v venah, ki lahko zamašijo pretok krvi do pljuč in povzročijo težave z dihanjem, bolečino v prsnem košu in razbijanje srca (palpitacije) - motnje srčnega ritma, pospešeno ali neenakomerno bitje srca (palpitacije), srčno popuščanje zaradi katerege težko dihate in lahko povzroči otekanje nog, zastoj srca.
English: It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose.
Slovenian: Priporočljivo je, da je infuzijska linija za zdravilo Caelyx prek stranskega nastavka priključena na intravensko infuzijo 5% (50 mg/ml) glukoze.
English: ○C and ANC < 1,000/mm
Slovenian: ○C z absolutnim številom nevtrofilcev (AŠN) < 1.000/mm
English: For the sub-group of patients with platinum-sensitive disease the difference was greater: HR of 1.432 (95% CI: 1.066; 1.923), p=0.017.
Slovenian: V podskupini bolnic z rakom, ki se je odzival na platinsko kemoterapijo, pa je bila ta razlika večja: razmerje med tveganji (HR) je bilo 1,432 (95% IZ; 1,066, 1,923), p=0,017.
English: In the pivotal phase III trial versus doxorubicin, 58/509 (11.4%) randomised subjects (10 treated with Caelyx at a dose of 50 mg/m2/every 4 weeks versus 48 treated with doxorubicin at a dose of
Slovenian: V osrednji raziskavi faze III, v kateri so zdravilo Caelyx primerjali s standardnim doksorubicinom, je 58 od 509 (11,4%) randomiziranih preiskovancev (od tega jih je bilo 10 zdravljenih z zdravilom Caelyx v odmerku 50 mg/m2 na vsake 4 tedne in 48 s standardnim doksorubicinom v odmerku
English: Stomatitis/mucositis and nausea were also commonly reported in breast/ovarian cancer patient populations, whereas the AIDS-KS Program (20 mg/m2 every 2 weeks), myelosuppression (mostly leukopaenia) was the most common side effect (see AIDS-KS).
Slovenian: Pri bolnicah z rakom dojk in rakom jajčnikov so pogosto poročali tudi o stomatitisu oz. mukozitisu ter navzei, medtem ko je bil v programu raziskav z aidsom povezanega Kaposijevega sarkoma (20 mg/m2 na vsaka 2 tedna) najpogostejši neželeni učinek mielosupresija, večinoma v smislu levkopenije (glejte poglavje o z aidsom povezanem Kaposijevem sarkomu).
English: Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.
Slovenian: Med sočasno uporabo drugih citotoksičnih zdravil, zlasti mielotoksičnih, je potrebna previdnost.
English: Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride.
Slovenian: Med sočasno uporabo zdravil, za katera je znano, da medsebojno delujejo s standardnim doksorubicinijevim kloridom, je potrebna previdnost.
English: Caelyx must not be given by the intramuscular or subcutaneous route.
Slovenian: Zdravila Caelyx ne smete dajati intramuskularno ali subkutano.
English: Caelyx in patients has not suggested a significant nephrotoxicity liability of Caelyx, these findings in monkeys may not have relevance to patient risk assessment.
Slovenian: Ker ovrednotenje podatkovne baze o varnosti zdravila Caelyx za bolnike v postmarketinškem obdobju ni pokazalo bistvene nefrotoksične obremenitve zaradi jemanja zdravila Caelyx, omenjeni izsledki pri opicah morda niso pomembni za oceno tveganja pri bolnikih.
English: You should tell your doctor about any of the following: - if you are receiving any treatment for heart disease or liver disease; - if you are diabetic, because Caelyx contains sugar which may require an adjustment to the treatment of your diabetes; - if you have Kaposi's sarcoma and have had your spleen removed; - if you notice sores, discolouration or any discomfort in your mouth.
Slovenian: Svojega zdravnika morate obvestiti, če imate kaj od naslednjega: - če prejemate kakršna koli zdravila za srčno ali jetrno bolezen - če imate sladkorno bolezen, saj zdravilo Caelyx vsebuje sladkor, zaradi česar bo morda treba prilagoditi zdravljenje sladkorne bolezni
English: * Palmar-plantar erythrodysesthesia (Hand-foot syndrome).
Slovenian: * Palmarno-plantarna eritrodisestezija (sindrom rok in stopal).
English: The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients.
Slovenian: Mediana vrednost TTP je znašala 6,5 mesecev pri bolnikih, ki so prejemali monoterapijo z bortezomibom, v primerjavi z vrednostjo 9,3 mesece pri tistih, ki so prejemali kombinirano terapijo z zdravilom Caelyx in bortezomibom.
English: Driving and using machines Do not drive or use any tools or machines if you feel tired or sleepy from treatment with Caelyx.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Če ste zaradi zdravljenja z zdravilom Caelyx utrujeni ali zaspani, ne upravljajte vozil in strojev.
English: In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride.
Slovenian: Pri bolnikih z aidsom so med uporabo standardnega doksorubicinijevega klorida opisali poslabšanje hemoragičnega cistitisa, ki ga je povzročila uporaba ciklofosfamida, in povečanje hepatotoksičnosti 6-merkaptopurina.
English: Table 4, below provides the schedule followed for other dose modifications in the clinical trial in the treatment of patients with multiple myeloma receiving Caelyx and bortezomib combination therapy.
Slovenian: V Preglednici 4 spodaj je podan načrt, ki so ga uporabljali za druge prilagoditve odmerka v kliničnem preskušanju zdravljenja bolnikov z diseminiranim plazmocitomom, ki prejemajo zdravilo Caelyx v kombinaciji z bortezomibom.
English: Given the difference in pharmacokinetic profiles and dosing schedules, Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.
Slovenian: Zaradi razlik v farmakokinetičnih značilnostih in režimu odmerjanja, zdravila Caelyx ne smete prosto zamenjevati z drugimi zdravili z doksorubicinijevim kloridom.
English: Caelyx concentrate for solution for infusion: vials which provide 10 ml (20 mg) or 25 ml (50 mg).
Slovenian: Caelyx 2 mg/ml koncentrat za raztopino za infundiranje: viale, ki vsebujejo po 10 ml (20 mg) ali 25 ml (50 mg) zdravilne učinkovine.
English: Caelyx is indicated: - As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
Slovenian: Zdravilo Caelyx je indicirano za zdravljenje: - Metastatskega raka dojk pri bolnicah s povečanim tveganjem za bolezni srca, v obliki monoterapije.
English: Caelyx is an antitumour agent.
Slovenian: Caelyx je zdravilo s protitumornim delovanjem.
English: With Caelyx, the encapsulation of doxorubicin hydrochloride in pegylated liposomes results in these effects having a differing strength, as follows.
Slovenian: Inkapsuliranost doksorubicinijevega klorida v pegiliranih liposomih pri zdravilu Caelyx povzroči, da imajo ti učinki drugačno jakost, kar je opisano v nadaljevanju.
English: Permanent treatment discontinuation was infrequently reported at 2%.
Slovenian: O dokončni prekinitvi zdravljenja so poročali redko, t.j.
English: This allows the Caelyx liposomes to circulate for prolonged periods in the blood stream.
Slovenian: To liposomom z zdravilom Caelyx omogoči, da dlje časa krožijo v krvnem obtoku.
English: If tolerated without reaction, the infusion rate was doubled for the next 15 minutes.
Slovenian: Če je bolnica to dobro prenašala in ni imela reakcije, so v naslednjih 15 minutah podvojili hitrost infundiranja.
English: Do not dose until recovered to grade < 2 and reduce dose by 25% for all subsequent doses.
Slovenian: Ne infundirajte zdravila, dokler bolnik ne okreva do stopnje toksičnosti < 2, potem pa pri vseh naslednjih odmerkih zmanjšajte velikost njegovega odmerka za 25% .
English: ** Grade 3/4 adverse events are based on the adverse event terms of all severities with an overall incidence ≥ 5% (see adverse events listed in first column).
Slovenian: ** Neželeni učinki 3. ali 4. stopnje so navedeni s termini pogostnosti za neželene učinke vseh jakosti s splošno incidenco
English: In patients with multiple myeloma receiving Caelyx plus bortezomib, infusion-associated reactions have been reported at a rate of 3%.
Slovenian: Pri bolnikih z diseminiranim plazmocitomom, ki so prejemali zdravilo Caelyx v kombinaciji z bortezomibom, so o infuzijskih reakcijah poročali s 3% pogostnostjo.
English: How to use Caelyx
Slovenian: Kako uporabljati zdravilo Caelyx
English: Grade 1 (painless ulcers, erythema, or mild soreness)
Slovenian: Stopnja 1 (neboleče razjede, eritem ali blage bolečine)
English: Metabolism and nutrition disorders common anorexia
Slovenian: Presnovne in prehranske motnje pogosti anoreksija
English: Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of Caelyx greater than 460 mg/m2 indicate no evidence of anthracycline-induced cardiomyopathy.
Slovenian: Pri devetih od desetih bolnikov, ki so imeli z aidsom povezani Kaposijev sarkom in so prejeli kumulativni odmerek zdravila Caelyx nad 460 mg/m2, endomiokardna biopsija ni pokazala nobenih znakov antraciklinske kardiomiopatije.
English: During the infusion of Caelyx, the following reactions may occur: flushing of the face, shortness of breath, headache, chills, back pain, tightness in the chest and/or throat, sore throat, low or increase in blood pressure, rapid heart beat, puffing of the face, fever, dizziness, nausea, indigestion, itching, rash and sweating.
Slovenian: Med infuzijo zdravila Caelyx se lahko pojavijo naslednje reakcije: rdečica obraza, težko dihanje, glavobol, mrzlica, bolečine v hrbtu, stiskanje v prsih in/ali žrelu, vnetje žrela, nizek ali zvišan krvni tlak, hiter srčni utrip, zabuhlost obraza, zvišana telesna temperatura, omotica, slabost, prebavne motnje, srbenje, izpuščaj in znojenje.
English: The mean intrinsic clearance of Caelyx was 0.030 l/h/m (range 0.008 to 0.152 l/h/m2) and the mean central volume of distribution was 1.93 l/m
Slovenian: Srednja vrednost intrinzičnega očistka zdravila Caelyx je 0,030 l/uro/m (razpon od 0,008 do 0,152 l/uro/m2), srednja vrednost osrednjega volumna porazdelitve pa 1,93 l/m
English: Pyridoxine (Vitamin B6): - vitamin B6 is available without prescription; - take 50-150 mg daily beginning at the first signs of redness or tingling.
Slovenian: Piridoksin (vitamin B6): - Vitamin B6 je na voljo brez recepta.
English: However, in contrast to the experience with patients with AIDS-KS, when Caelyx was compared to a standard treatment for advanced ovarian cancer (topotecan), the risk of infections was substantially lower in the Caelyx-treated patients.
Slovenian: Toda v nasprotju z izkušnjami pri bolnikih z aidsom in Kaposijevem sarkomom je bila nevarnost za okužbe pri bolnicah z napredovalim rakom jajčnikov, ki so prejemale Caelyx, bistveno manjša kot pri standardnem zdravljenju raka jajčnikov (topotekan).
English: The pharmacokinetics of Caelyx was evaluated in 120 patients from 10 different clinical trials using the population pharmacokinetic approach.
Slovenian: Farmakokinetiko zdravila Caelyx so ovrednotili po načelih populacijske farmakokinetike pri 120 bolnikih iz 10 različnih kliničnih raziskav.